In this study, we conducted an indirect comparison analysis to compare the efficacy and safety of immune checkpoint inhibitors with those of antiangiogenic therapy—two effective treatment methods for ...

Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor ...

There are currently 2 widely accepted treatment strategies for MS: escalation and induction therapy. Escalation therapy begins with agents that are associated with less pronounced risk, but also may ...

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). Results from a first-in-human phase I study of ...

Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis ...

In December 2019, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in Wuhan, China 1. It causes highly infectious Coronavirus Disease 2019 (COVID-19) to spread ...

Researchers conducted an indirect treatment comparison (Bucher method) using placebo as a common comparator to evaluate the efficacy of dupilumab and tezepelumab in patients with CRSwNP. The analysis ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS – Matching-adjusted indirect comparisons found a positive benefit-risk profile for ozanimod vs.

Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 ...